Senseonics Holdings, Inc. (NYSE:SENS) Receives Average Rating of “Buy” from Analysts

Senseonics Holdings, Inc. (NYSE:SENS) has been given an average recommendation of “Buy” by the six analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $22.70.

A number of brokerages have recently commented on SENS. HC Wainwright upped their price target on Senseonics to $18.50 and gave the company a “buy” rating in a research note on Thursday, November 6th. Stifel Nicolaus began coverage on shares of Senseonics in a research note on Tuesday, October 21st. They issued a “hold” rating and a $9.00 target price for the company. Barclays reissued an “overweight” rating and set a $31.00 price target (up from $1.50) on shares of Senseonics in a research report on Wednesday, November 5th. Finally, TD Cowen decreased their price target on shares of Senseonics from $25.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday, November 5th.

Insider Buying and Selling at Senseonics

In other Senseonics news, Director Edelman Steven acquired 10,000 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The stock was acquired at an average cost of $6.55 per share, for a total transaction of $65,500.00. Following the transaction, the director owned 74,708 shares of the company’s stock, valued at $489,337.40. This trade represents a 15.45% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Douglas A. Roeder bought 15,000 shares of the company’s stock in a transaction on Friday, November 7th. The shares were bought at an average price of $5.83 per share, for a total transaction of $87,450.00. Following the completion of the acquisition, the director directly owned 99,727 shares in the company, valued at approximately $581,408.41. This trade represents a 17.70% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders acquired 30,415 shares of company stock valued at $184,790. Company insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Senseonics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. State of Wyoming bought a new stake in Senseonics in the 1st quarter valued at approximately $40,000. Goldman Sachs Group Inc. lifted its position in shares of Senseonics by 26.2% in the first quarter. Goldman Sachs Group Inc. now owns 612,534 shares of the company’s stock worth $402,000 after purchasing an additional 127,086 shares in the last quarter. CTC Alternative Strategies Ltd. acquired a new position in Senseonics during the first quarter worth $31,000. Elite Life Management LLC bought a new position in Senseonics in the second quarter valued at $36,000. Finally, Keynote Financial Services LLC increased its stake in Senseonics by 1,120.2% in the 2nd quarter. Keynote Financial Services LLC now owns 208,285 shares of the company’s stock valued at $99,000 after buying an additional 191,215 shares during the last quarter. Institutional investors and hedge funds own 12.36% of the company’s stock.

Senseonics Stock Down 5.8%

Shares of Senseonics stock opened at $5.67 on Tuesday. The business has a fifty day simple moving average of $6.44 and a 200 day simple moving average of $8.48. The stock has a market cap of $231.67 million, a PE ratio of -43.62 and a beta of 0.92. The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17. Senseonics has a 12 month low of $5.25 and a 12 month high of $28.00.

Senseonics Company Profile

Senseonics Holdings, Inc is a medical technology company focused on the development and commercialization of innovative continuous glucose monitoring (CGM) systems for people with diabetes. Since its founding in 2011 and headquartered in Germantown, Maryland, the company has pioneered an implantable sensor designed to deliver long-term glucose readings. Senseonics’ mission centers on improving diabetes management by providing accurate, real-time data to patients and healthcare providers.

The company’s flagship offering is the Eversense CGM System, which features a small, fully implantable sensor placed beneath the skin to measure glucose levels for up to 90 days in the United States and up to 180 days in Europe.